癌症生物治疗市场规模、份额、成长分析，按产品、按癌症类型、按阶段、按给药途径、按分销管道、按最终用户、按地区 - 行业预测，2025 年至 2032 年

全球癌症生物治疗市场规模预计从 2024 年的 912.7 亿美元增长至 2032 年的 1,603.7 亿美元，到 2023 年将达到 850.6 亿美元，预计在预测期内（2025 年）的复合年增长率为 1.2%。 -2032）。

受癌症发生率上升和专科治疗中心出现的推动，全球癌症生物治疗市场将迎来显着成长。专家们正在利用奈米技术的力量开发创新的治疗方案，为先进的治疗和个人化的患者照护铺平道路。对生物疗法日益重视，加上技术的进步，可望改变癌症治疗，为全球患者提供更有效、个人化的治疗方法。随着研究的进步和创新解决方案的出现，市场将大幅扩张并加强对这种毁灭性疾病的持续斗争。技术创新与不断增长的患者需求相结合，为该领域在不久的将来带来了前所未有的机会。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 专利分析

癌症生物治疗市场规模（按产品）

• 市场概况
• 单株抗体（MAB）
  • 裸露的MAB
  • 共轭单株抗体
  • 双特异性MAB
• 疫苗
  • 预防疫苗
  • 治疗性疫苗
• 癌症生长抑制剂
  • 蛋白酪氨酸激酶抑制剂 (TKI)
  • 蛋白酶体抑制剂 (PI)
  • mTOR 抑制剂
• 血球生长因子（BCGF）
  • 来诺司亭
  • Filgrastim
• 细胞激素
  • 干扰素
  • 白细胞介素

癌症生物治疗市场规模（按癌症类型）

• 市场概况
• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌

癌症生物治疗市场规模（按阶段）

• 市场概况
• 第一阶段
• 第二阶段
• 第三阶段

按给药途径分類的癌症生物治疗市场规模

• 市场概况
• 口服
• 注射

癌症生物治疗市场规模（按分销管道）

• 市场概况
• 专门癌症治疗中心
• 医院和诊所
• 零售药局

癌症生物治疗市场规模（按最终用户划分）

• 市场概况
• 医院
• 居家护理
• 专业中心
• 其他的

癌症生物治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• AstraZeneca（United Kingdom）
• Pfizer（United States）
• Bristol Myers Squibb（United States）
• Novartis（Switzerland）
• Merck & Co.（United States）
• Roche Holding AG（Switzerland）
• Amgen Inc.（United States）
• Gilead Sciences（United States）
• Eli Lilly and Company（United States）
• Johnson & Johnson（United States）
• Sanofi（France）
• GlaxoSmithKline（United Kingdom）
• Takeda Pharmaceutical Company（Japan）
• Biogen Inc.（United States）
• Regeneron Pharmaceuticals（United States）
• Moderna Inc.（United States）
• BioNTech SE（Germany）
• Incyte Corporation（United States）
• Exelixis, Inc.（United States）

结论和建议

Global Cancer Biological Therapy Market size was valued at USD 85.06 billion in 2023 and is poised to grow from USD 91.27 billion in 2024 to USD 160.37 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global cancer biological therapy market is set for remarkable growth, fueled by the increasing incidence of cancer and the emergence of specialized treatment facilities. Experts are harnessing the power of nanotechnology to develop innovative therapeutic solutions, paving the way for advanced treatments and personalized patient care. The heightened emphasis on biological therapies, combined with technological advancements, is expected to transform cancer care, enabling more effective and tailored treatment options for patients worldwide. As research progresses and innovative solutions emerge, the market is poised for extraordinary expansion, enhancing the ongoing battle against this devastating disease. This convergence of innovation and growing patient needs positions the sector for unprecedented opportunities in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biological Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biological Therapy Market Segmental Analysis

Global Cancer Biological Therapy Market is segmented by Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users and region. Based on Product, the market is segmented into Monoclonal antibodies (MAB), Vaccines, Cancer growth blockers, Blood cell growth factors (BCGF) and Cytokines. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer. Based on Phases, the market is segmented into Phase I, Phases II and Phases III. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Specialized Cancer Treatment Centers, Hospitals & Clinics and Retail Pharmacies. Based on End-Users, the market is segmented into Hospitals, Homecare, Speciality Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biological Therapy Market

One of the primary factors driving the global cancer biological therapy market is the rising incidence of cancer cases across the globe. Recent statistics from the American Cancer Society indicate a concerning increase in Small Cell Lung Cancer (SCLC), predominantly affecting individuals aged 60 to 80. With an estimated annual death toll of about 30,000 from SCLC and lung cancer being the second most common type in both genders-resulting in 1.59 million fatalities as of 2012 per the World Health Organization-these sobering numbers highlight the urgent need for innovative cancer treatments. Consequently, there is a growing demand for cancer biological therapies to effectively combat this escalating health crisis.

Restraints in the Global Cancer Biological Therapy Market

One notable restraint in the Global Cancer Biological Therapy market is the high cost associated with cancer treatment options. The substantial expenses related to these therapies create a significant barrier for many patients, particularly those in rural regions who may struggle to access the necessary funds. This financial strain limits the ability of a large portion of the population to afford essential treatments, thus impeding overall market growth. As a result, the prohibitive pricing of cancer biological therapies remains a critical challenge that needs to be addressed to enhance accessibility and improve patient outcomes in the healthcare system.

Market Trends of the Global Cancer Biological Therapy Market

The global cancer biological therapy market is witnessing a prominent trend towards personalized and targeted therapies, driven by advancements in genomics and molecular biology. As researchers gain deeper insights into the unique genetic and molecular characteristics of various tumors, there is a growing demand for biologic treatments tailored to the specific genetic abnormalities or biomarkers present in patients' cancer cells. This focus on customization enhances treatment efficacy, minimizes adverse effects, and improves overall patient outcomes. By efficiently targeting the molecular underpinnings of tumors, these innovative therapies are transforming oncology, leading to significant market growth as healthcare systems increasingly adopt personalized approaches to cancer treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Patent Analysis

Global Cancer Biological Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Monoclonal antibodies (MAB)
  • Naked MAB
  • Conjugated MAB
  • Bispecific MAB
• Vaccines
  • Preventive vaccines
  • Therapeutic vaccines
• Cancer growth blockers
  • Tyrosine kinase inhibitors (TKI)
  • Proteasome inhibitors (PI)
  • mTOR inhibitors
• Blood cell growth factors (BCGF)
  • Lenograstim
  • Filgrastim
• Cytokines
  • Interferons
  • Interleukins

Global Cancer Biological Therapy Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

Global Cancer Biological Therapy Market Size by Phases & CAGR (2025-2032)

• Market Overview
• Phase I
• Phases II
• Phases III

Global Cancer Biological Therapy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Cancer Biological Therapy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Specialized Cancer Treatment Centers
• Hospitals & Clinics
• Retail Pharmacies

Global Cancer Biological Therapy Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Speciality Centres
• Others

Global Cancer Biological Therapy Market Size & CAGR (2025-2032)

• North America (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • US
  • Canada
• Europe (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations